Evidence map›Paper›PMID 34876040›Full record

ArticleBMC cancer2021

FAM83H-AS1/miR-485-5p/MEF2D axis facilitates proliferation, migration and invasion of hepatocellular carcinoma cells.

Wenpeng Zhao, Jiang Guo, Honglu Li, Liang Cai, Youjia Duan, Xiaopu Hou, Zhenying Diao, Xihong Shao, Hongliu Du, Changqing Li

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wenpeng ZhaoDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Jiang GuoDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Honglu LiDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Liang CaiDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Youjia DuanDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Xiaopu HouDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Zhenying DiaoDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Xihong ShaoDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Hongliu DuDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China.
Changqing LiDepartment of Oncology Interventional Radiology, Beijing Ditan Hospital, Capital Medical University, No.8 Jingshundong Road, Beijing, 100015, China. changqing0402@163.com.
Capital Medical University · CN

Funding

Research fund Program of Beijing Ditan Hospital DTDR201806
6 · The paper itself

Abstract

backgroundAbundant evidence has manifested that long noncoding RNAs (lncRNAs) are closely implicated in human cancers, including hepatocellular carcinoma (HCC). Remarkably, lncRNA FAM83H antisense RNA 1 (FAM83H-AS1) has been reported to be a tumor-propeller in multiple cancers. However, its effect on HCC progression remains unknown.

methodsFAM83H-AS1 expression was analyzed by RT-qPCR. Colony formation, EdU, and flow cytometry as well as transwell assays were implemented to analyze the biological functions of FAM83H-AS1 on HCC progression. Luciferase reporter, RIP and RNA pull-down assays were implemented to detect the interaction among FAM83H-AS1, microRNA-485-5p (miR-485-5p), and myocyte enhancer factor 2D (MEF2D) in HCC cells.

resultsFAM83H-AS1 expression in HCC cells was markedly elevated. FAM83H-AS1 accelerated cell proliferation, migration and invasion whereas inhibiting cell apoptosis in HCC. Besides, we confirmed that FAM83H-AS1 acts as a miR-485-5p sponge in HCC cells. Additionally, MEF2D was verified to be a direct target of miR-485-5p. FAM83H-AS1 could upregulate MEF2D expression via sponging miR-485-5p. Further, rescue experiments testified that MEF2D upregulation or miR-485-5p downregulation offset the repressive effect of FAM83H-AS1 depletion on HCC cell progression.

conclusionsFAM83H-AS1 facilitates HCC malignant progression via targeting miR-485-5p/MEF2D axis, suggesting that FAM83H-AS1 may be a promising biomarker for HCC treatment in the future.

Indexed as

ApoptosisBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationDisease ProgressionHumansLiver NeoplasmsMEF2 Transcription FactorsMicroRNAsNeoplasm InvasivenessProteinsReal-Time Polymerase Chain ReactionRNA, AntisenseBiomarkers, TumorFAM83H protein, humanMEF2D protein, humanMEF2 Transcription FactorsMicroRNAsMIRN485 microRNA, humanProteinsRNA, AntisenseFAM83H-AS1HCCMEF2DmiR-485-5p

Identifiers

PMID34876040
PMCPMC8650424
OpenAlexW4200273764

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.